Cargando…
Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena
The introduction of immune checkpoint inhibitor (ICI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and has dramatically improved the outcomes of patients. The use of monotherapy or combinations of ICIs targeting PD-1/PD-L1 and CTLA-4, as well as the addition of ICIs wit...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571056/ https://www.ncbi.nlm.nih.gov/pubmed/37842239 http://dx.doi.org/10.20517/cdr.2023.47 |